CAPE TOWN, SA / ACCESSWIRE / December 18, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update:
The Company is set to expand into the European market with its recently launched Medspresso™ line of CBD infused hot beverages. Medspresso™ is a premium functional beverages brand that encompasses a current product line of CBD-infused African coffees, teas and hot chocolates. The recent launch in early November has drummed up numerous inquiries from around the globe. The company is planning to ship its first international order to Cafféluxe Limited International in January 2021.
Michael Sachar, Cafféluxe Commercial Director said:
“The interest has been nothing short of phenomenal. We will move the Medspresso™ range through existing distributors in the UK, Europe and GCC countries (Middle East). “
The company is scaling up its production to meet the growing demand. Currently, the products are available at the Cafféluxe showroom and E-commerce websites across South Africa.
“The market response for Medspresso™ has been nothing short of spectacular. Consumers are loving the products and the brand. We will always work as hard as we can to earn and keep the loyalty of our consumers by delivering exceptional products far beyond expectations. ”
said Wuhan General Group CEO Jeff Robinson.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is listed and traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
For further information:
Sign up for MORE news updates !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.